Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

7:20 AM ET 8-K
Clinical Trial Data Faeth Therapeutics, Inc. FTH

Faeth Therapeutics Clinical Trial Data

Faeth Therapeutics reported positive topline Phase 2 results from its PIK-201 trial evaluating PIKTOR in combination with paclitaxel for advanced endometrial cancer. The trial achieved a 33% confirmed objective response rate (ORR) and a median progression-free survival of 7.4 months, supporting the company's plan to advance the program into a Phase 3 registrational trial.

Counterparty
The GOG Foundation, Inc.
7:07 AM ET 8-K
Clinical Trial Data Zura Bio Ltd ZURA

Zura Bio Clinical Trial Data

Zura Bio announced that its Phase 2 TibuSHIELD study of tibulizumab (ZB-106) in adults with moderate-to-severe hidradenitis suppurativa (HS) failed to meet its primary endpoint of percentage change from baseline in total abscess and inflammatory nodule count at Week 16. Key secondary endpoints were also not met, leading the company to discontinue development of the drug for the HS indication. Zura will continue its ongoing trials for tibulizumab in systemic sclerosis and polymyalgia rheumatica.

7:03 AM ET 8-K
Divestiture NRG Energy, Inc. NRG

NRG Energy Divestiture to LS Power for $4B

NRG Energy has agreed to sell six natural-gas fired generation assets totaling 4.9 GW to an affiliate of LS Power for $4 billion in cash. The transaction includes assets in NYISO, ISO-NE, and ERCOT and is expected to close in the second quarter of 2027. Proceeds will be used to fund $3 billion in share repurchases across 2026-2027 and $3 billion in debt reduction.

Value
$4B
Counterparty
LS Power
7:01 AM ET 8-K
Capital Raise Precision Biosciences Inc DTIL

Precision Biosciences Capital Raise

Precision BioSciences provided an update on its previously announced public offering of 10,235,077 shares of common stock and 5,893,964 pre-funded warrants. The company expects the net proceeds to extend its cash runway into the fourth quarter of 2029, providing sufficient capital to fund its PBGENE-HBV and PBGENE-DMD clinical programs through key inflection points.

6:34 AM ET 8-K
Clinical Trial Data ImmunityBio, Inc. IBRX

ImmunityBio Clinical Trial Data

ImmunityBio announced that its QUILT-2.005 trial of ANKTIVA plus BCG met its primary efficacy endpoint in patients with BCG-naïve non-muscle invasive bladder cancer (NMIBC). The combination therapy showed a statistically significant improvement in efficacy compared to BCG alone, and the company plans to submit a supplemental Biologics License Application (sBLA) to the FDA by year-end 2026.

6:31 AM ET 8-K
M&A Deal Abeona Therapeutics Inc. ABEO

Abeona Therapeutics Signs $20M M&A Deal with Ellodi Pharmaceuticals, L.P.

Abeona Therapeutics acquired substantially all assets related to APT-1011 (now ABO-801), a Phase 3-ready candidate for eosinophilic esophagitis, from Ellodi Pharmaceuticals. The deal was structured with $20 million in upfront equity consideration (4,494,383 shares) and no upfront cash, with Ellodi eligible for $30 million upon FDA approval and up to $30 million in sales milestones plus royalties.

Value
$20M
Counterparty
Ellodi Pharmaceuticals, L.P.

“The acquisition of ABO-801 is an important step in building Abeona into a diversified commercial-stage company with multiple opportunities for value inflection, adding an asset with substantial revenue potential in a rapidly growing disease.”

Vish Seshadri, Ph.D., Chief Executive Officer of Abeona Therapeutics
6:21 AM ET 8-K
Capital Raise Ckx Lands, Inc. CKX

Ckx Lands Capital Raise of $1B

CKX Lands entered into a definitive investment agreement for a $1 billion equity investment led by Brad Jacobs and Jacobs Private Equity II, LLC. Upon closing, Jacobs will become Chairman and CEO, and the company will be renamed and repurposed as a standalone platform for a new multibillion-dollar venture in an industry to be determined.

Value
$1B
Counterparty
Jacobs Private Equity II, LLC
6:15 AM ET 8-K
Product Launch Canton Strategic Holdings, Inc. CNTN

Canton Strategic Holdings Product Launch

Canton Strategic Holdings announced the first trades of its issuer-sponsored tokenized common stock on TSV, a permissioned venue on the Canton Network. The transactions were executed under the SEC’s Innovation Exemption and involved institutional participants including DRW Cumberland and Flowdesk. This marks the first time a U.S. National Market System (NMS) stock has been tokenized and traded on-chain with an SEC-registered transfer agent.

Counterparty
TSV LLC
6:14 AM ET 8-K
M&A Deal Charles River Laboratories International, Inc. CRL

Charles River Laboratories International Signs $470M M&A Deal with Frontage Holdings Corporation

Charles River Laboratories has entered into definitive agreements to acquire Frontage Holdings Corporation’s bioanalysis and DMPK operations in Exton, Pennsylvania for $470 million in cash. The deal includes up to $75 million in additional contingent payments and is intended to expand Charles River's clinical bioanalysis capabilities to support clients across the full drug development lifecycle. The transaction is expected to close in the first half of 2027.

Value
$470M
Counterparty
Frontage Holdings Corporation
6:07 AM ET 8-K
Product Launch Artificial Intelligence Technology Solutions Inc. AITX

Artificial Intelligence Technology Solutions Product Launch

Artificial Intelligence Technology Solutions' subsidiary, Robotic Assistance Devices (RAD), has launched RAIA, a portable solar-powered security tower designed for rapid one-person deployment. The compact system ships via parcel carriers and can be set up in approximately 15 minutes without specialized towing equipment. The company expects to begin deliveries in late Q1 2027, targeting the $1.5 billion global mobile surveillance tower market.

6:05 AM ET 8-K
Licensing Deal Edesa Biotech, Inc. EDSA

Edesa Biotech Licensing Deal with Kyorin Pharmaceutical Co., Ltd. Worth $146M

Edesa Biotech granted Kyorin Pharmaceutical an exclusive license to develop and commercialize its anti-TLR4 monoclonal antibody, paridiprubart (EB05), for the treatment of ARDS in Japan. Edesa receives a $12 million upfront payment and is eligible for up to $134 million in development, regulatory, and sales milestones, plus tiered double-digit royalties. Kyorin will fund all development and commercialization activities in Japan while Edesa retains rights in all other territories.

Value
$146M
Counterparty
Kyorin Pharmaceutical Co., Ltd.
Term
15 years
6:05 AM ET 8-K
Clinical Trial Data Cabaletta Bio, Inc. CABA

Cabaletta Bio Clinical Trial Data

Cabaletta Bio presented Phase 1/2 clinical data for rese-cel (CABA-201) at the ACR Convergence 2026 meeting, demonstrating durable, immunomodulator-free responses across multiple autoimmune diseases. Key results showed 100% of dermatomyositis patients maintained moderate-to-major improvement scores through one year and 100% of biopsied lupus nephritis patients achieved DORIS remission. The company plans to report topline registrational data in H2 2027 and submit a Biologics License Application in Q1 2028.

“In three different autoimmune diseases where patients are at risk of severe disability, end-organ damage, and increased risk of death despite current therapies, a single weight-based dose of rese-cel delivered immunomodulator-free clinical improvements that were durable through at least one year with a favorable benefit-risk profile.”

David J. Chang, M.D., Chief Medical Officer of Cabaletta

“We believe these emerging data reinforce the potential of rese-cel to deliver an immune reset that leads to durable efficacy with a favorable benefit-risk profile for autoimmune disease patients.”

David J. Chang, M.D., Chief Medical Officer of Cabaletta
6:04 AM ET 8-K
Capital Raise Valion Bio, Inc. VBIO

Valion Bio Capital Raise of $700K

Valion Bio, Inc. completed a $700,000 closing under its existing Series B Preferred Purchase Agreement with 3i, LP, issuing 700 shares of Series B Non-Voting Convertible Preferred Stock and warrants to purchase 21,539 shares of common stock. As part of the agreement, the company committed to filing a registration statement for the resale of the underlying common shares within 30 days and extended the outside date for future closings to December 9, 2027.

Value
$700K
Counterparty
3i, LP
6:03 AM ET 8-K/A
M&A Deal TruGolf Holdings, Inc. TRUG

TruGolf Holdings M&A Deal with Polymath Research Inc.

TruGolf Holdings, Inc. filed an amendment to its previous 8-K to provide required financial statements and pro forma information following its acquisition of Polymath Research Inc. The acquisition of the Canadian-based research firm was completed on October 8, 2026, pursuant to an agreement originally dated August 17, 2026.

Counterparty
Polymath Research Inc.
6:03 AM ET 8-K
Capital Raise Third Point Private Capital Income Fund

Third Point Private Capital Income Fund Capital Raise of $4M

Third Point Private Capital Income Fund issued and sold 160,000 Class S common shares to Delticus Opportunities Fund LLC for $4.0 million. The sale was conducted as a capital drawdown under a subscription agreement where Delticus has committed to purchase up to $15 million in common shares. Delticus is an affiliate of the Fund's investment adviser.

Value
$4M
Counterparty
Delticus Opportunities Fund LLC
6:02 AM ET 8-K
Capital Raise SPACCircle Acquisition Corp. SCQC

SPACCircle Acquisition Capital Raise

SPACCircle Acquisition Corp. announced that holders of the units issued in its initial public offering may elect to separately trade the underlying Class A ordinary shares, warrants, and rights starting November 10, 2026. The separated securities will trade on the Nasdaq Global Market under the symbols SCQC, SCQCW, and SCQCR, respectively.

5:30 PM ET 8-K
M&A Deal Pono Capital Four, Inc. PONO

Pono Capital Four Signs $200M M&A Deal with Blackstar Orbital Technologies Corporation

Pono Capital Four, Inc. entered into an amendment to its existing merger agreement with Blackstar Orbital Technologies Corporation, reducing the base purchase price from $380 million to $200 million. The amendment also increases the shares reserved for the post-closing equity incentive plan and extends the outside closing date from March 31, 2027, to June 30, 2027.

Value
$200M
Counterparty
Blackstar Orbital Technologies Corporation
5:27 PM ET 8-K
M&A Deal Rallybio Corp RLYB

Rallybio M&A Deal with Avenzo Therapeutics, Inc.

Rallybio Corporation has postponed the closing of its previously announced merger with Avenzo Therapeutics, Inc., which was originally expected to close on November 6, 2026. The delay is due to unsatisfied conditions related to the listing of the company's shares following the transaction. Consequently, the company has also delayed the funding and payment of its previously announced cash distribution to shareholders.

Counterparty
Avenzo Therapeutics, Inc.
5:25 PM ET 8-K
Nasdaq/NYSE Compliance Notice Knightscope, Inc. KSCP

Knightscope Nasdaq/NYSE Compliance Notice

Knightscope received a deficiency notice from Nasdaq because its Class A Common Stock closed below the $1.00 minimum bid price for 30 consecutive business days. The company has 180 calendar days, until May 3, 2027, to regain compliance by maintaining a bid price of at least $1.00 for ten consecutive business days. The notice does not result in immediate delisting, and the stock continues to trade under the symbol 'KSCP'.

Counterparty
Nasdaq
Term
180 days
5:25 PM ET 8-K
M&A Deal T3 Defense Inc. DFNS

T3 Defense Signs $1.54M M&A Deal with KeepZone AI Inc.

T3 Defense Inc. completed the acquisition of KeepZone AI Inc. from Nexera Technologies Ltd. on November 4, 2026. The purchase price was increased to $1,539,800 and was settled through the issuance of 425,594 shares of T3 Defense common stock.

Value
$1.54M
Counterparty
KeepZone AI Inc.
5:25 PM ET 8-K
Capital Raise Mangoceuticals, Inc. MGRX

Mangoceuticals Capital Raise

Mangoceuticals, Inc. received written consent from its Series B Preferred Stock holder to establish a new series of 8% Series D Convertible Cumulative Preferred Stock. The company plans to offer up to 1,000,000 shares of the Series D Preferred Stock at $10.00 per share through a Regulation A offering. The Series B holder also approved an amendment to recognize the senior dividend and liquidation rights of the new Series D shares.

5:11 PM ET 8-K
Capital Raise Biovie Inc. BIVI

Biovie Capital Raise of $4.74M

BioVie Inc. entered into a securities purchase agreement with an institutional investor for a $4.74 million registered direct offering and concurrent private placement. The company issued 960,000 shares and 2,002,500 pre-funded warrants at $1.60 per share/equivalent, along with 2,962,500 common warrants. Proceeds are intended for working capital and general corporate purposes.

Value
$4.74M
5:10 PM ET 8-K
Divestiture Kontoor Brands, Inc. KTB

Kontoor Brands Divestiture to Authentic Brands Group for $750M

Kontoor Brands completed the sale of its Lee business to an affiliate of Authentic Brands Group for $750 million in cash. The deal includes an additional $250 million earnout opportunity based on the performance of the Lee business over the next five years. The divestiture allows Kontoor to focus on its remaining portfolio, including the Wrangler and Helly Hansen brands.

Value
$750M
Counterparty
Authentic Brands Group
Term
5 years
5:08 PM ET 8-K
Capital Raise Silo Pharma, Inc. SILO

Silo Pharma Capital Raise of $850K

Silo Pharma entered into securities purchase agreements with accredited investors for a private placement of 136,005 common shares and 430,661 pre-funded warrants. The offering is expected to generate approximately $815,000 in net proceeds for working capital and general corporate purposes. The company also agreed to file a registration statement for the resale of the securities within 30 days of the agreement.

Value
$850K
5:01 PM ET 8-K
M&A Deal HeartSciences Inc. HSCS

HeartSciences M&A Deal with Fortitude Mining Holdings, Inc.

HeartSciences Inc. provided a status update regarding its pending merger with Fortitude Mining HoldCo, LLC, a subsidiary of Digital Currency Group. The company issued supplemental proxy disclosures to address demand letters from purported shareholders alleging disclosure omissions, aiming to avoid potential litigation delays ahead of the November 19, 2026, shareholder vote.

Counterparty
Fortitude Mining Holdings, Inc.
5:01 PM ET 8-K
Capacity Expansion AST SpaceMobile, Inc. ASTS

AST SpaceMobile Capacity Expansion

AST SpaceMobile announced plans to build its own 20-ton rocket to deploy its BlueBird satellites in low-Earth orbit. The company will utilize Miranda engines from Firefly Aerospace for the launch vehicle, representing a major vertical integration of its satellite deployment infrastructure.

Counterparty
Firefly Aerospace, Inc.
4:50 PM ET 8-K
M&A Deal NorthWestern Energy Group, Inc. NWE

NorthWestern Energy Group M&A Deal with Black Hills

NorthWestern Energy Group management is attending the EEI Financial Conference to provide a strategic update and reaffirm its 2026 non-GAAP earnings guidance. The accompanying presentation includes forward-looking details regarding a pending merger with Black Hills, including anticipated financial results, strategic rationale, and regulatory progress. The company reaffirmed its 2026 earnings guidance range of $3.68 to $3.83 per diluted share.

Counterparty
Black Hills
4:47 PM ET 8-K
M&A Deal Lazard, Inc. LAZ

Lazard M&A Deal with Campbell Lutyens Holdings Limited

Lazard, Inc. filed a prospectus supplement to facilitate the potential resale of up to 9,416,817 shares of common stock by selling stockholders. These shares were previously issued as consideration for Lazard's acquisition of 100% of Campbell Lutyens Holdings Limited. The filing serves to register these shares for secondary sale, and Lazard will receive no proceeds from any such sales.

Counterparty
Campbell Lutyens Holdings Limited
4:32 PM ET 8-K
Capital Raise American Healthcare REIT, Inc. AHR

American Healthcare REIT Capital Raise

American Healthcare REIT, Inc. entered into a new at-the-market (ATM) equity offering sales agreement to sell up to $1.75 billion of its common stock. This new program replaces a prior ATM facility established in February 2026, which had approximately $170.1 million remaining unsold at the time of termination. The shares may be sold from time to time through a syndicate of agents including BofA Securities, Citigroup, and Morgan Stanley.

Counterparty
BofA Securities, Inc.
4:31 PM ET 8-K
M&A Deal Victory Capital Holdings, Inc. VCTR

Victory Capital Holdings Signs $7.03B M&A Deal with GC Ferry Holdings, Inc.

Victory Capital Holdings provided a status update on its pending $7.03 billion acquisition of First Eagle, which was originally announced in August 2026. The filing discloses that the company is facing stockholder litigation and demand letters alleging that the proxy statement related to the deal contains materially incomplete and misleading disclosures. Victory intends to issue supplemental disclosures to the proxy statement to moot these claims and avoid potential delays to the transaction closing.

Value
$7.03B
Counterparty
GC Ferry Holdings, Inc. (First Eagle)

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.